## Abstract Huntington's disease‐like 2 is an autosomal dominantly inherited disorder due to an expansion of trinucleotide repeats. It resembles classic Huntington's disease in clinical phenotype, inheritance pattern, and neuropathological features. We highlight the clinical features of this disord
Huntington's disease-like 2 in Brazil—Report of 4 patients
✍ Scribed by Guilherme G. Riccioppo Rodrigues; Ruth H. Walker; Alexis Brice; Cécile Cazeneuve; Odile Russaouen; Helio A.G. Teive; Renato Puppi Munhoz; Nilson Becker; Salmo Raskin; Lineu Cesar Werneck; Wilson Marques Junior; Vitor Tumas
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 225 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Huntington's disease‐like 2 (HDL2) is a neurodegenerative disorder found in people of African ancestry with clinical, radiological, and neuropathological manifestations similar to Huntington's disease (HD). HDL2 is caused by a pathological expansion of CAG/CTG triplets in exon 2A of the JPH3 gene. We describe four cases of HDL2 from four unrelated families, and discuss their clinical findings. HDL2 should be considered in every patient with an HD‐like phenotype who tests negative for the HD mutation, even if African ancestry is not immediately apparent. © 2008 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract Huntington's Disease–like 2 (HDL2) is a progressive, autosomal dominant, neurodegenerative disorder with marked clinical and pathological similarities to Huntington's disease (HD). The causal mutation is a CTG/CAG expansion mutation on chromosome 16q24.3, in a variably spliced exon of j
## Abstract The aim of this study was to assess the criterion validity of three self‐report measures of depression in a sample of patients with Huntington's disease (HD). Fifty patients with HD completed the Beck Depression Inventory‐II (BDI‐II), the Hospital Anxiety and Depression Scale (HADS), an
## Abstract Little is known about subjective perceptions of quality of life (QOL) in Huntington's disease (HD). The current study determined correlates of patient and caregiver QOL and assessed change over time. Participants were 22 patient‐caregiver dyads, who rated QOL at baseline and 6 months la